GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » Intrinsic Value: Projected FCF

ME Therapeutics Holding (XCNQ:METX) Intrinsic Value: Projected FCF : C$0.00 (As of Jun. 14, 2024)


View and export this data going back to 2023. Start your Free Trial

What is ME Therapeutics Holding Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-06-14), ME Therapeutics Holding's Intrinsic Value: Projected FCF is C$0.00. The stock price of ME Therapeutics Holding is C$4.00. Therefore, ME Therapeutics Holding's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for ME Therapeutics Holding's Intrinsic Value: Projected FCF or its related term are showing as below:

XCNQ:METX's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.17
* Ranked among companies with meaningful Price-to-Projected-FCF only.

ME Therapeutics Holding Intrinsic Value: Projected FCF Historical Data

The historical data trend for ME Therapeutics Holding's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ME Therapeutics Holding Intrinsic Value: Projected FCF Chart

ME Therapeutics Holding Annual Data
Trend Aug22 Aug23
Intrinsic Value: Projected FCF
- -

ME Therapeutics Holding Quarterly Data
Aug22 Dec22 May23 Aug23 Nov23 Feb24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial - - - - -

Competitive Comparison of ME Therapeutics Holding's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, ME Therapeutics Holding's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ME Therapeutics Holding's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ME Therapeutics Holding's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where ME Therapeutics Holding's Price-to-Projected-FCF falls into.



ME Therapeutics Holding Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



ME Therapeutics Holding  (XCNQ:METX) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

ME Therapeutics Holding's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=4.00/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ME Therapeutics Holding Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of ME Therapeutics Holding's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


ME Therapeutics Holding (XCNQ:METX) Business Description

Comparable Companies
Traded in Other Exchanges
Address
177 Robson Street, Vancouver, BC, CAN, V6B 0N3
ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.

ME Therapeutics Holding (XCNQ:METX) Headlines

No Headlines